Checkpoint inhibitors linked to longer unadjusted progression-free survival in advanced thoracic tumors
A single-center cohort study linked checkpoint inhibitor-containing therapy with longer unadjusted progression-free survival in advanced SMARCA4-deficient thoracic tumors, but adjusted ...
